RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Medlab Clinical Stock

Medlab Clinical Liabilities 2025

Medlab Clinical Liabilities

962,260.01 AUD

Ticker

MDC.AX

ISIN

AU000000MDC8

WKN

A14R7W

In 2025, Medlab Clinical's total liabilities amounted to 962,260.01 AUD, a -48.39% difference from the 1.86 M AUD total liabilities in the previous year.

Medlab Clinical Aktienanalyse

What does Medlab Clinical do?

Medlab Clinical Ltd is an innovative biotechnology company focused on the development and commercialization of medical products and services. The company was founded in Australia in 2012 and is now based in Sydney. Since its founding, Medlab has established itself as a leading provider of diagnostic and therapeutic products. Medlab's business model consists of three different divisions. The first division is pharmaceutical development, where Medlab works on the development of new medications for the treatment of conditions such as fibromyalgia, pain, or ADHD. Medlab is particularly innovative in the development of medications based on the use of cannabinoids that are approved for medical use. The second division of Medlab is the research and development of nutritional supplements. The company works on the development of innovative products to improve general well-being and support health. An example is the nutritional supplement NRGBiotic, which contains special probiotic bacteria that help regulate the intestinal flora and thereby strengthen the immune system. The third division of Medlab is clinical diagnostics. The company offers various medical diagnostic tests, such as the test for food intolerances. This test is based on a blood sample and allows for targeted dietary changes in individuals with intolerance. Medlab aims to improve people's lives by developing and providing innovative products and services for medical care. Medlab's products are designed to promote the health and well-being of patients and customers and improve their quality of life. One outstanding product from Medlab is NanoCBD, an innovative form of cannabinoid delivery for medical purposes. The advantage of NanoCBD is that it has increased bioavailability due to the nanoparticles, resulting in faster and more effective action than conventional CBD products. Another product from Medlab is the pain medication NanaBis, which works faster and more effectively than other pain medications due to its unique formulation. Thanks to its special composition, NanaBis can also be taken by patients with severe chronic pain who do not respond to other pain medications. Medlab has established itself as a global company and is present worldwide. The company maintains partnerships and collaborations with renowned research institutions and doctors in Europe, North America, Australia, and Asia. Medlab works closely with medical professionals to ensure that the company's products and services meet the highest quality standards and meet the needs of patients and customers. Overall, Medlab Clinical Ltd has established itself as an innovative and reliable company in the medical industry. With its clear focus on the development of innovative medications, nutritional supplements, and diagnostic systems, Medlab significantly contributes to improving the healthcare system and increasing the well-being of people worldwide. Medlab Clinical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Medlab Clinical's Liabilities

Medlab Clinical's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Medlab Clinical's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Medlab Clinical's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Medlab Clinical's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Medlab Clinical’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Medlab Clinical stock

What is the level of liabilities of Medlab Clinical this year?

Medlab Clinical has a debt balance of 962,260.01 AUD this year.

What were the liabilities of Medlab Clinical compared to the previous year?

The liabilities of Medlab Clinical have increased by -48.39% dropped compared to the previous year.

What are the consequences of high debt for investors of Medlab Clinical?

High liabilities can pose a risk for investors of Medlab Clinical, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Medlab Clinical?

Low liabilities mean that Medlab Clinical has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Medlab Clinical affect the company?

An increase in liabilities of Medlab Clinical can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Medlab Clinical affect the company?

A decrease in the liabilities of Medlab Clinical can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Medlab Clinical?

Some factors that can influence the liabilities of Medlab Clinical include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Medlab Clinical so important for investors?

The liabilities of Medlab Clinical are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Medlab Clinical take to modify the liabilities?

To change its liabilities, Medlab Clinical can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Medlab Clinical pay?

Over the past 12 months, Medlab Clinical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medlab Clinical is expected to pay a dividend of 0 AUD.

What is the dividend yield of Medlab Clinical?

The current dividend yield of Medlab Clinical is .

When does Medlab Clinical pay dividends?

Medlab Clinical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medlab Clinical?

Medlab Clinical paid dividends every year for the past 0 years.

What is the dividend of Medlab Clinical?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Medlab Clinical located?

Medlab Clinical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medlab Clinical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medlab Clinical from 1/29/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 1/29/2025.

When did Medlab Clinical pay the last dividend?

The last dividend was paid out on 1/29/2025.

What was the dividend of Medlab Clinical in the year 2024?

In the year 2024, Medlab Clinical distributed 0 AUD as dividends.

In which currency does Medlab Clinical pay out the dividend?

The dividends of Medlab Clinical are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Medlab Clinical

Our stock analysis for Medlab Clinical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medlab Clinical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.